HOME >> BIOLOGY >> NEWS
AVANT to develop an oral anthrax and plague vaccine for U.S. Department of Defense

This release has been updated as of Monday January 21st.

NEEDHAM, MA (January 22, 2003): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing. AVANT executed the subcontract with DynPort Vaccine Company LLC ("DVC"), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.

"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of AVANT to conduct this development program is an important recognition of the strength of AVANT's vaccine and vector technologies for accomplishing these aims."

"This contract is very important to AVANT since it provides non-dilutive funding to the company and it means that AVANT now has over two years of cash and cash equivalents on hand," Dr. Ryan concluded.

Senator Edward M. Kennedy (D-MA), Ranking Dem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-281-2413
Kureczka/Martin Associates
22-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Wisconsin scientists develop quick botox test
5. Bronfenbrenner book sums up human development
6. Researchers develop fast track way to discover how cells are regulated
7. DuPont developing new protective suits for military, first responders
8. OutFoxed! New research may redefine late-stage cardiac development
9. Computer scientists at UH developing nurturing computers
10. Disease diagnosis, drug development focus of UH profs biochip research
11. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies

Post Your Comments:
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. is ... and Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences to ... Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from samples ...
(Date:6/26/2015)... ... 26, 2015 , ... Claremont BioSolutions, LLC, a pioneer of ... into a sample prep module intended to enable real-time quantitative gene expression analysis ... WetLab-2 Project. , On June 28, 2015, SpaceX CRS-7 will launch from Cape ...
(Date:6/26/2015)... 26, 2015 The report "Biolubricants ... Fluids, Metalworking fluids, Chainsaw oils, Mold Release Agents), End ... - Global trends and Forecasts to 2020" published by ... Million by 2020 at a CAGR of 6.27% between ... data Tables and   66 Figures spread through 170 ...
(Date:6/25/2015)... , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/vxtfvv/2015_market ) has announced the addition ... of the Global Cancer Diagnostics Industry: ... Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3
Cached News: